These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 971701)

  • 1. Observations on the efficacy and pharmacokinetics of sotalol after oral administration.
    Brown HC; Carruthers SG; Kelly JG; McDevitt DG; Shanks RG
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):367-72. PubMed ID: 971701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol.
    Harron DW; Balnave K; Kinney CD; Wilson R; Russell CJ; Shanks RG
    Clin Pharmacol Ther; 1981 Mar; 29(3):295-302. PubMed ID: 7471600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.
    Leahey WJ; Neill JD; Varma MP; Shanks RG
    Eur J Clin Pharmacol; 1980 Jun; 17(6):419-24. PubMed ID: 7398733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans.
    Funck-Brentano C; Kibleur Y; Le Coz F; Poirier JM; Mallet A; Jaillon P
    Circulation; 1991 Feb; 83(2):536-45. PubMed ID: 1846784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of once daily sotalol administration in man.
    McDewitt DG; Shanks RG
    Br J Clin Pharmacol; 1977 Apr; 4(2):153-6. PubMed ID: 861130
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of once and twice daily sotalol in exercise-induced angina pectoris.
    Wilhelmsson C; Vedin A; Ulvenstam G; Aberg A; Descamps R; Thomis JA
    Eur J Clin Pharmacol; 1982; 21(6):461-5. PubMed ID: 7075651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of oral sotalol in suppression of premature ventricular complexes and analysis of its beta-adrenergic blocking activity.
    Giorgi C; Nadeau R; Agha A; Primeau R; de Champlain J
    Can J Cardiol; 1990 Jun; 6(5):191-7. PubMed ID: 1696514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blunting of exercise-induced tachycardia and renin release 24 hours after a single dose of sotalol.
    Kiowski W; Bühler FR; Van Brummelen P; Küng M
    J Clin Pharmacol; 1979; 19(8-9 Pt 2):513-5. PubMed ID: 489769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.
    McDevitt DG; Brown HC; Carruthers SG; Shanks RG
    Clin Pharmacol Ther; 1977 May; 21(5):556-66. PubMed ID: 15753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)-sotalol in healthy volunteers.
    Uematsu T; Kanamaru M; Nakashima M
    J Pharm Pharmacol; 1994 Jul; 46(7):600-5. PubMed ID: 7996391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
    Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
    Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. d-sotalol reduces heart rate in vivo through a beta-adrenergic receptor-independent mechanism.
    Yasuda SU; Barbey JT; Funck-Brentano C; Wellstein A; Woosley RL
    Clin Pharmacol Ther; 1993 Apr; 53(4):436-42. PubMed ID: 8386603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Plasma level and action of sotalol-HCL on the ECG interval after parenteral administration in healthy subjects].
    Rehm KD; Schnelle K; Dyde CJ; Blümner E; Arendts W
    Arzneimittelforschung; 1987 Sep; 37(9):1058-62. PubMed ID: 3435602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive effects of practolol and sotalol.
    Sundquist H; Anttila M; Arstila M
    Clin Pharmacol Ther; 1974 Sep; 16(3):465-72. PubMed ID: 4606232
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics in young normal and elderly hypertensive subjects: a study using sotalol as a model drug.
    Ishizaki T; Hirayama H; Tawara K; Nakaya H; Sato M; Sato K
    J Pharmacol Exp Ther; 1980 Jan; 212(1):173-81. PubMed ID: 6101341
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers.
    Kimura M; Umemura K; Ikeda Y; Kosuge K; Mizuno A; Nakanomyo H; Ohashi K; Nakashima M
    Br J Clin Pharmacol; 1996 Nov; 42(5):583-8. PubMed ID: 8951189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observations on some properties of a long-acting preparation of propranolol.
    Shanks RG; Neill JD; Leahey WJ; Varma MP
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():409s-411s. PubMed ID: 540460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels and half-life of sotalol in chronic renal failure.
    Sundquist HK; Anttila M; Forsström J; Kasanen A
    Ann Clin Res; 1975 Dec; 7(6):442-6. PubMed ID: 1211858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.
    Brown HC; Carruthers SG; Johnston GD; Kelly JG; McAinsh J; McDevitt DG; Shanks RG
    Clin Pharmacol Ther; 1976 Nov; 20(5):524-34. PubMed ID: 10125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects.
    Barbey JT; Sale ME; Woosley RL; Shi J; Melikian AP; Hinderling PH
    Clin Pharmacol Ther; 1999 Jul; 66(1):91-9. PubMed ID: 10430114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.